Olema Pharmaceuticals, Inc. (OLMA) announced an amendment to its existing clinical collaboration and supply agreement with Novartis Institutes for BioMedical Research, Inc. to increase the size of the ongoing Phase 1/2 clinical study testing palazestrant in combination with ribociclib to approximately 60 patients. The expanded study supports the potential late-stage development of palazestrant in first-line advanced or metastatic breast cancer in combination with ribociclib.
Olema signed a clinical collaboration and supply agreement with Novartis in July 2020. The agreement was amended and restated in January 2022. The amendment adds approximately 30 patients to be enrolled in the cohort expansion phase of the clinical study.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.